CONSTANT LEVERAGE LONG - ELI LILLY & CO | Market Closed - Euronext Paris 10:00:02 07/06/2024 pm IST | ||
| 14.15 EUR | +18.61% |
|
| Current month | +43.95% | ||
| 1 month | +107.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 07/24/07 | 13.56 | +13.66% |
| 06/24/06 | 11.93 | +3.20% |
| 05/24/05 | 11.56 | +7.64% |
| 04/24/04 | 10.74 | -5.37% |
| 03/24/03 | 11.35 | +20.49% |
Real-time Euronext Paris
Last update June 07, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| YL5NB | |
| ISIN | NLBNPNL2OS34 |
| Date issued | 13/03/2024 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.58 € |
|---|---|
| Lowest since issue | 3.905 € |
| Spread | 0.36 € |
| Spread % | 2.51% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
850
USD
Average target price
853.8
USD
Spread / Average Target
+0.44%
- Stock Market
- Certificates
- YL5NB Certificat
